4.8 Article

Plasmonic-doped melanin-mimic for CXCR4-targeted NIR-II photoacoustic computed tomography-guided photothermal ablation of orthotopic hepatocellular carcinoma

Journal

ACTA BIOMATERIALIA
Volume 129, Issue -, Pages 245-257

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.actbio.2021.05.034

Keywords

Small hepatocellular carcinoma; Melanin-mimic; Second near-infrared (NIR-II); Photoacoustic imaging; Photothermal therapy

Funding

  1. National Science Foundation Major Research Instrumentation Program [81627805]
  2. National Key RD Program [2016YFC0106500]
  3. NSFC-GD Union Foundation [U1401254]
  4. National Natural Science Foundation of China [81930048, 22077108]
  5. National High Technology Research and Development Program of China (863 program) [2006AA02Z346, 2012AA021105]
  6. University Grants Committee of Hong Kong SAR [11101618, 11215817, 11103320, R5029-19]
  7. Hong Kong Innovation and Technology Commission [GHP/043/19SZ, GHP/044/19GD]

Ask authors/readers for more resources

This study demonstrates the first diagnostic NIR-II photoacoustic computed tomography (PACT)-guided noninvasive photothermal ablation of small hepatocellular carcinoma (SHCC) using a polydopamine-based melanin-mimic tumor-targeting nanoagent doped with plasmonic platinum. The nanoagent selectively targets CXCR4-overexpressed HepG2 carcinoma cells and tumor lesions, serving as a theranostic agent for both NIR-II PACT-based diagnosis of orthotopic SHCC and efficient NIR-II PTT in vivo. Additionally, the study extends the potential of melanin-derived blackbody materials for optical-biomedical and water distillation applications.
Effective and noninvasive diagnosis and prompt treatment of early-stage hepatocellular carcinoma (HCC) are urgently needed to reduce its mortality rate. Herein, the integration of high-resolution diagnostic second near-infrared (NIR-II) photoacoustic computed tomography (PACT) and imaging-guided targeted photothermal ablation of orthotopic small HCC (SHCC) is presented for the first time, which was en-abled by a plasmonic platinum (Pt)-doped polydopamine melanin-mimic nanoagent. As designed, an antibody-modified nanoagent (designated Pt@PDA-c) with a plasmonic blackbody-like NIR absorption and superior photothermal conversion efficiency (71.3%) selectively targeted and killed CXCR4-overexpressing HCC (HepG2) cells, which was validated in in vitro experiments. The targeted accumulation properties of Pt@PDA-c in vivo were previously recognized by demonstrating effective NIR-II PA imaging and photother-mal ablation in a subcutaneous HCC mouse model. Subsequently, with real-time quantitative guidance by PACT for the accurate diagnosis of intraabdominal SHCC (approximately 4 mm depth), the effective and noninvasive photothermal ablation of SHCCs was successfully demonstrated in an orthotopic tumor-bearing mouse model without damaging adjacent liver tissues. These results show a great potential of NIR-II PACT-guided noninvasive photothermal therapy as an innovative phototheranostic approach and expand the biomedical applications of melanin-mimic materials. Statement of significance In this paper, we report the first diagnostic NIR-II photoacoustic computed tomography (PACT)-guided noninvasive photothermal ablation of small hepatocellular carcinoma (SHCC) located in deep tissues in orthotopic tumor-bearing mice; this process is empowered by a polydopamine-based melanin-mimic tumor-targeting nanoagent doped with plasmonic platinum that provides superior NIR-II (1064 nm) ab-sorption and photothermal conversion efficiency of 71.3%. Following surface modification with anti-CXCR4 antibodies, the nanoagent (namely Pt@PDA-c) can selectively target CXCR4-overexpressed HepG2 carci-noma cells and tumor lesions, and serve as the theranostic agent for both NIR-II PACT-based diagnosis of orthotopic SHCC (diameter less than 5 mm) and efficient NIR-II PTT in vivo. This study may also ex-tend the potential of melanin-derived blackbody materials for optical-biomedical and water distillation applications. (c) 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available